Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
The Benzinga Stock Whisper highlights five stocks weekly that are seeing increased interest from readers. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Smart Money Is Betting Big In VKTX Options ↗
 
Via Benzinga
News headline image
Is Viking Therapeutics Stock a Buy? ↗
The stock could have room to soar higher if VK2735 obtains approval from regulators. 
Via The Motley Fool
News headline image
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
News headline image
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Viking Therapeutics? ↗
 
Via Benzinga
News headline image
Viking Therapeutics's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Tiny but Mighty: 3 Small-Cap Stocks Crushing the Russell 2000 ↗
Top small-cap stocks to buy Viking Therapeutics, Celsius and Hippo make waves in the weight loss, energy drink, and insurance tech sectors. 
Via InvestorPlace
News headline image
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
News headline image
How Viking Therapeutics Stock Could 30x ↗
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
News headline image
Is Viking Therapeutics the Best Biotech Stock for You? ↗
With good mid-stage results and plenty of cash, Viking could be a winner. 
Via The Motley Fool
News headline image
The 3 Best Russell 2000 Stocks to Buy in May 2024 ↗
If you are looking for investments that will deliver high returns, these are the best Russell 2000 stocks to buy for your portfolio. 
Via InvestorPlace
News headline image
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025 ↗
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
News headline image
Check Out What Whales Are Doing With VKTX ↗
 
Via Benzinga
News headline image
Can This High-Flying Stock 10x in 10 Years? ↗
This midcap biotech could see huge success ahead -- or disappointment. 
Via The Motley Fool
News headline image
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
News headline image
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
News headline image
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now? ↗
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
News headline image
What Is the Best Weight Loss Stock to Buy Now? Our Top 3 Picks ↗
Data indicates that many more Americans have become aware of the dangers of obesity. Here are the best weight loss stocks to buy now. 
Via InvestorPlace
News headline image
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge ↗
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount. 
Via InvestorPlace
News headline image
Viking Therapeutics Unusual Options Activity ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Is Viking Therapeutics Incredibly Undervalued? ↗
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound. 
Via The Motley Fool
News headline image
1 Little-Known Vanguard Index Fund to Buy Before It Soars 50%, According to a Wall Street Analyst ↗
Tom Lee of Fundstrat Global Advisors thinks the small-cap Russell 2000 could climb 50% by the end of 2024. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Buy on the Dip: April 2024 ↗
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
News headline image
3 Millionaire-Maker Biotech Stocks ↗
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
News headline image
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024 ↗
VKTX stock results show that Viking Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO ↗
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.